BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 15157660)

  • 1. Enhancement of radiotherapy with DNA topoisomerase I-targeted drugs.
    Chen AY; Chou R; Shih SJ; Lau D; Gandara D
    Crit Rev Oncol Hematol; 2004 May; 50(2):111-9. PubMed ID: 15157660
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeted radiosensitization with DNA topoisomerase I drugs.
    Chen AY; Phan C; Chang YC; Shih SJ
    Discov Med; 2004 Jun; 4(22):208-12. PubMed ID: 20704988
    [TBL] [Abstract][Full Text] [Related]  

  • 3. DNA topoisomerase I-targeting drugs as radiation sensitizers.
    Chen AY; Choy H; Rothenberg ML
    Oncology (Williston Park); 1999 Oct; 13(10 Suppl 5):39-46. PubMed ID: 10550825
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current perspectives on the clinical experience, pharmacology, and continued development of the camptothecins.
    Garcia-Carbonero R; Supko JG
    Clin Cancer Res; 2002 Mar; 8(3):641-61. PubMed ID: 11895891
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanisms of resistance to topoisomerase I-targeting drugs.
    Rasheed ZA; Rubin EH
    Oncogene; 2003 Oct; 22(47):7296-304. PubMed ID: 14576839
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Induction of radiosensitization by indolocarbazole derivatives: the role of DNA topoisomerase I.
    Chen AY; Shih SJ; Hsiao M; Rothenberg ML; Prudhomme M
    Mol Pharmacol; 2004 Sep; 66(3):553-60. PubMed ID: 15322247
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential induction of topoisomerase I-DNA cleavage complexes by the indenoisoquinoline MJ-III-65 (NSC 706744) and camptothecin: base sequence analysis and activity against camptothecin-resistant topoisomerases I.
    Antony S; Jayaraman M; Laco G; Kohlhagen G; Kohn KW; Cushman M; Pommier Y
    Cancer Res; 2003 Nov; 63(21):7428-35. PubMed ID: 14612542
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cellular, pharmacokinetic, and pharmacodynamic aspects of response to camptothecins: can we improve it?
    Jung LL; Zamboni WC
    Drug Resist Updat; 2001 Aug; 4(4):273-88. PubMed ID: 11998845
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel camptothecin derivatives.
    Legarza K; Yang LX
    In Vivo; 2005; 19(1):283-92. PubMed ID: 15796188
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Can the therapeutic gain of radiotherapy be increased by concurrent administration of Asian botanicals?
    Sagar SM
    Integr Cancer Ther; 2010 Mar; 9(1):5-13. PubMed ID: 20042406
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New radiosensitizing regimens, drugs, prodrugs, and candidates.
    Vallerga AK; Zarling DA; Kinsella TJ
    Clin Adv Hematol Oncol; 2004 Dec; 2(12):793-805. PubMed ID: 16166960
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Silatecan DB-67 is a novel DNA topoisomerase I-targeted radiation sensitizer.
    Chen AY; Shih SJ; Garriques LN; Rothenberg ML; Hsiao M; Curran DP
    Mol Cancer Ther; 2005 Feb; 4(2):317-24. PubMed ID: 15713902
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antimetabolite radiosensitizers.
    Shewach DS; Lawrence TS
    J Clin Oncol; 2007 Sep; 25(26):4043-50. PubMed ID: 17827452
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New and emerging radiosensitizers and radioprotectors.
    Spalding AC; Lawrence TS
    Cancer Invest; 2006; 24(4):444-56. PubMed ID: 16777698
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mammalian DNA topoisomerase I mediates the enhancement of radiation cytotoxicity by camptothecin derivatives.
    Chen AY; Okunieff P; Pommier Y; Mitchell JB
    Cancer Res; 1997 Apr; 57(8):1529-36. PubMed ID: 9108456
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of indenoisoquinoline topoisomerase I inhibitors using a hollow fiber assay.
    Morrell A; Jayaraman M; Nagarajan M; Fox BM; Meckley MR; Ioanoviciu A; Pommier Y; Antony S; Hollingshead M; Cushman M
    Bioorg Med Chem Lett; 2006 Aug; 16(16):4395-9. PubMed ID: 16750365
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Type I DNA topoisomerase from protozoan pathogens as a potential target for anti-tumoral drugs].
    Reguera RM; Pérez-Pertejo Y; Redondo CM; Díaz-González R; Balaña-Fouce R
    Medicina (B Aires); 2007; 67(6 Pt 2):747-57. PubMed ID: 18422072
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Radiosensitising agents for the radiotherapy of cancer: advances in traditional and hypoxia targeted radiosensitisers.
    Bischoff P; Altmeyer A; Dumont F
    Expert Opin Ther Pat; 2009 May; 19(5):643-62. PubMed ID: 19441939
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Radiation sensitization with redox modulators: a promising approach.
    Rosenberg A; Knox S
    Int J Radiat Oncol Biol Phys; 2006 Feb; 64(2):343-54. PubMed ID: 16414370
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.